VentiV Scientific

Executive Summary

VentiV Scientific is a private medical device company headquartered in San Diego, California, founded in 2018. The company specializes in developing advanced mechanical thrombectomy systems for vascular interventions, addressing critical needs in peripheral arterial, venous, and access procedures. Its flagship product, the V-Pulse™ system, employs a novel mechanism featuring tip-level suction with controlled, pulsed clot engagement. This design aims to efficiently remove thrombus while minimizing blood loss, potentially offering advantages over existing aspiration or stent retriever technologies. The company targets the growing peripheral vascular intervention market, where thrombectomy procedures are increasing due to rising incidences of deep vein thrombosis, pulmonary embolism, and peripheral artery disease. Despite limited public information on funding or commercial traction, VentiV Scientific's focused technology and experienced management (implied by its founding in 2018) position it as a potential innovator in the interventional vascular space. Given the early-stage nature of the company and the competitive landscape of thrombectomy devices, VentiV Scientific faces significant regulatory and commercial hurdles. The company has not disclosed its total funding, valuation, or stage, suggesting it may be operating in stealth or early clinical phases. Success will depend on obtaining regulatory clearances (e.g., FDA 510(k) or CE marking) and demonstrating clinical superiority over established players like Penumbra, Medtronic, and Inari Medical. The nearest catalysts include regulatory milestones and potential clinical data releases. Overall, the conviction is moderate, reflecting the promise of the V-Pulse technology tempered by the lack of available data and competitive risks.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance of V-Pulse system for peripheral thrombectomy70% success
• Q4 2026Presentation of first-in-human or preclinical data at a major vascular conference (e.g., VIVA, TCT)60% success
• H2 2026Series A or seed funding announcement to support clinical development50% success